MiR-564 acts as a dual inhibitor of PI3K and MAPK signaling networks and inhibits proliferation and invasion in breast cancer
dc.citation.epage | 14 | en_US |
dc.citation.spage | 1 | en_US |
dc.citation.volumeNumber | 6 | en_US |
dc.contributor.author | Mutlu, M. | en_US |
dc.contributor.author | Saatci, Ö. | en_US |
dc.contributor.author | Ansari, S. A. | en_US |
dc.contributor.author | Yurdusev, E. | en_US |
dc.contributor.author | Shehwana, H. | en_US |
dc.contributor.author | Konu, Ö. | en_US |
dc.contributor.author | Raza, U. | en_US |
dc.contributor.author | Şahin, Ö. | en_US |
dc.date.accessioned | 2018-04-12T10:49:16Z | |
dc.date.available | 2018-04-12T10:49:16Z | |
dc.date.issued | 2016 | en_US |
dc.department | Department of Molecular Biology and Genetics | en_US |
dc.description.abstract | Dysregulation of PI3K and MAPK pathways promotes uncontrolled cell proliferation, apoptotic inhibition and metastasis. Individual targeting of these pathways using kinase inhibitors has largely been insufficient due to the existence of cross-talks between these parallel cascades. MicroRNAs are small non-coding RNAs targeting several genes simultaneously and controlling cancer-related processes. To identify miRNAs repressing both PI3K and MAPK pathways in breast cancer, we re-analyzed our previous miRNA mimic screen data with reverse phase protein array (RPPA) output, and identified miR-564 inhibiting both PI3K and MAPK pathways causing markedly decreased cell proliferation through G1 arrest. Moreover, ectopic expression of miR-564 blocks epithelial-mesenchymal transition (EMT) and reduces migration and invasion of aggressive breast cancer cells. Mechanistically, miR-564 directly targets a network of genes comprising AKT2, GNA12, GYS1 and SRF, thereby facilitating simultaneous repression of PI3K and MAPK pathways. Notably, combinatorial knockdown of these target genes using a cocktail of siRNAs mimics the phenotypes exerted upon miR-564 expression. Importantly, high miR-564 expression or low expression of target genes in combination is significantly correlated with better distant relapse-free survival of patients. Overall, miR-564 is a potential dual inhibitor of PI3K and MAPK pathways, and may be an attractive target and prognostic marker for breast cancer. © The Author(s) 2016. | en_US |
dc.description.provenance | Made available in DSpace on 2018-04-12T10:49:16Z (GMT). No. of bitstreams: 1 bilkent-research-paper.pdf: 179475 bytes, checksum: ea0bedeb05ac9ccfb983c327e155f0c2 (MD5) Previous issue date: 2016 | en |
dc.identifier.doi | 10.1038/srep32541 | en_US |
dc.identifier.issn | 2045-2322 | |
dc.identifier.uri | http://hdl.handle.net/11693/36700 | |
dc.language.iso | English | en_US |
dc.publisher | Nature Publishing Group | en_US |
dc.relation.isversionof | http://dx.doi.org/10.1038/srep32541 | en_US |
dc.source.title | Scientific Reports | en_US |
dc.title | MiR-564 acts as a dual inhibitor of PI3K and MAPK signaling networks and inhibits proliferation and invasion in breast cancer | en_US |
dc.type | Article | en_US |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- MiR-564 acts as a dual inhibitor of PI3K and MAPK signaling networks and inhibits proliferation and invasion in breast cancer.pdf
- Size:
- 2.6 MB
- Format:
- Adobe Portable Document Format
- Description:
- Full Printable Version